Halozyme Therapeutics Inc. (HALO)
Halozyme Therapeutics (HALO) Surpasses Q1 Earnings and Revenue Estimates
Halozyme Therapeutics (HALO) came out with quarterly earnings of $1.11 per share, beating the Zacks Consensus Estimate of $0.95 per share. This compares to earnings of $0.79 per share a year ago.
Halozyme Therapeutics: Still Undervalued Ahead Of Earnings
Halozyme Therapeutics, Inc. remains a buy due to its strong subscription-based business model, high growth, and undervaluation. HALO's robust product library, focused on drug delivery systems, positions it well to avoid sector issues and continue outperforming the market. The company has shown consistent revenue growth, high gross margins, and strong returns on investments, with a fair value estimated at $67.71.
Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?
Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Halozyme Therapeutics (HALO) is a Top-Ranked Value Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Halozyme Joins the $1 Billion Club
Halozyme Therapeutics, Inc. (HALO) shares up after passing $1 billion in revenue for first time, strong guidance.
Halozyme Stock Offers Early Buy Point As Company Hits $1 Billion In Revenue
Halozyme stock is in a consolidation pattern but its chart shows an alternate entry. The biotech name hit two milestones in 2024.
HALO vs. AMGN: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Halozyme Therapeutics (HALO) and Amgen (AMGN). But which of these two companies is the best option for those looking for undervalued stocks?
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Is Halozyme Therapeutics (HALO) a Solid Growth Stock? 3 Reasons to Think "Yes"
Halozyme Therapeutics (HALO) possesses solid growth attributes, which could help it handily outperform the market.
Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
HALO's Q4 Earnings Beat, Higher Royalties Drive Revenue Growth
Halozyme reports better-than-expected fourth-quarter 2024 results. The company maintains revenue guidance for 2025.
Halozyme Therapeutics, Inc. (HALO) Q4 2024 Earnings Call Transcript
Halozyme Therapeutics, Inc. (HALO) Q4 2024 Earnings Call Transcript
